[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552593":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":72,"collaborators":31,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":31,"enrollmentInfo":84,"targetDuration":31,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":50,"whyStopped":31,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Universitas Diponegoro","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (Oral Acetazolamide)","EXPERIMENTAL","Participants who received intravenous furosemide plus acetazolamide 250 mg \u002F 12 hours orally for up to 3 days.",[13],"Drug: Oral Acetazolamide",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B (Placebo)","PLACEBO_COMPARATOR","Participants who received intravenous furosemide plus Placebo \u002F 12 hours orally for up to 3 days.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oral Acetazolamide","Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days",[9],[27],"Glauseta",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Placebo",[15],null,[33],{"name":34,"affiliation":35,"role":36},"Ilham Uddin, MD","Department Cardiology and Vascular Medicine Universitas Diponegoro Kariadi General Hospital","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Inne P Farissa, MD","CONTACT","024-8413476","6282","innefarissa@gmail.com",{"name":45,"role":40,"phone":41,"phoneExt":42,"email":46},"Tahari B Prakoso, MD","ibas_tbargasp@yahoo.com",[48,65],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Department of Cardiology and Vascular Medicine, Universitas Diponegoro, Kariadi Central General Hospital","RECRUITING","Semarang","Central Java","50244","Indonesia","ID",{"type":57,"coordinates":58},"Point",[59,60],110.42083,-6.99306,{"lat":60,"lon":59},[63,64],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":34,"role":36,"phone":31,"phoneExt":31,"email":31},{"facility":66,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Kariadi Central General Hospital",{"type":57,"coordinates":68},[59,60],{"lat":60,"lon":59},[71],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":36,"investigatorFullName":34,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"MD, FAsCC, FSCAI","100552593","phase-4-combination-oral-acetazolamide-and-intravenous-furosemide-on-acute-decompensated-heart-failure-outcomes-100552593",false,"NCT06475105","Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes","Effects of Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure","COAF-HF","Inclusion Criteria:\n\n* Agree to be included in the research by signing informed consent\n* Patients with a clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload with a congestion score ≥2 (ADVOR Score) (e.g. edema (score 2 or more), ascites confirmed by physical examination or ultrasonography or pleural effusion confirmed by chest x-ray or echocardiography).\n* Patients on routine oral loop diuretic therapy with a dose of ≥40 mg furosemide for ≥1 month\n* Plasma NT-proBNP levels that increase ≥300 pg\u002FmL or the applicable cut-off according to the age range at the time of examination in the ER.\n\nExclusion Criteria:\n\n* Subjects with acute coronary syndrome\n* History of congenital heart disease requiring surgical correction.\n* Subjects in cardiogenic shock.\n* Estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73m² at the time of examination.\n* Use of renal replacement therapy or ultrafiltration at any time before the study was included.\n* Treatment with acetazolamide within 1 month before randomization.\n* Exposure to nephrotoxic agents (i.e. contrast dye) is anticipated within the next 3 days\n* Subjects who are pregnant or breastfeeding.\n* Subjects with urinary incontinence who are unwilling to use a bladder catheter.","ALL","18 Years",{"count":85,"type":86},66,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.\n\nThe hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.",[92],"Acute Decompensated Heart Failure",[23,92,94],"Congestion","2024-10-20",{"date":97,"type":98},"2024-10-22","ACTUAL",{"date":100,"type":98},"2024-04-20",{"date":102,"type":86},"2024-12-31",{"name":5,"class":6},2]